Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS – YES
نویسندگان
چکیده
منابع مشابه
Disease-modifying therapies in relapsing–remitting multiple sclerosis
CLINICAL QUESTION What is the best current disease-modifying therapy for relapsing-remitting multiple sclerosis? RESULTS The evidence shows that the most effective disease-modifying therapy for delaying short- to medium-term disability progression, prevention of relapses, reducing the area and activity of lesions on magnetic resonance imaging, with the least side effects, is high-dose, high-f...
متن کاملEffects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis
Background: Progressive brain atrophy is a major feature of multiple sclerosis (MS) pathology and is actually considered a major determinant of the progressive accumulation of physical and cognitive disability in MS patients. Although brain atrophy may have different pathological substrates, several lines of evidence suggest that in disease modifying drug (DMD)-treated MS patients, the higher i...
متن کاملEfficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison.
The treatment of relapsing-remitting multiple sclerosis (RRMS) has become more effective over the last decade with the advent of the currently available disease-modifying therapies (DMTs). Pivotal clinical studies differ in many characteristics, such that cross-comparisons of relative risk reductions are of limited value and can be misleading. Our objective was to compare the clinical efficacy ...
متن کاملTreatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
BACKGROUND Treatment satisfaction in patients with relapsing-remitting multiple sclerosis (RRMS) may impact adherence and thus clinical outcomes. The objective of this study was to measure the satisfaction of patients with RRMS with injectable disease-modifying therapies (DMTs) and to evaluate the factors associated with treatment satisfaction. MATERIAL AND METHODS In this observational retro...
متن کاملNeurofilament light chain predicts disease activity in relapsing-remitting MS
Objective To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods A cohort of 85 patients with RRMS were followed for 2 years (6 months without disease-modifying treatment and 18 months with interferon-beta 1a [IFNB-1a]). Expanded Disability Status Scale was scored at baseline and every 6 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Journal
سال: 2017
ISSN: 1352-4585,1477-0970
DOI: 10.1177/1352458517709957